Compare Vanguard Intermediate Term Corporate Bond ETF (VCIT) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Intermediate Term Corporate Bond ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Intermediate Term Corporate Bond ETF trades at $81.17, while GeneDx Holdings Corp trades at $82 (market cap $2.44B). The key difference: GeneDx Holdings Corp is trading nearer its 52-week high, Vanguard Intermediate Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| VCIT | WGS | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $84.82 | $167.51 |
52-Week Low | $81.07 | $34.51 |
Market Cap | — | $2.44B |
Enterprise Value | — | $2.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VCIT, the Vanguard Intermediate-Term Corporate Bond ETF, trades at $81.20 with a slight 0.16% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund maintains consistent monthly dividend distributions, with recent payouts around $0.33-$0.34. News highlights VCIT's competitive 0.03% expense ratio and approximately 5% yield compared to peers like iShares corporate bond ETFs, emphasizing its cost efficiency for income-focused investors.
The outlook for VCIT is mixed, offering attractive income through corporate bond exposure but facing interest rate sensitivity. Opportunities include high relative yield and low fees, while risks involve corporate credit deterioration and Fed policy shifts. Investors should weigh yield advantages against potential volatility from economic changes.
GeneDx Holdings Corp (WGS) trades at $82.39, up 5.79% in the past 24 hours, with a bullish technical signal and strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating guidance, and returned to adjusted profitability earlier than expected. However, net income remains negative at -$106 million for 2026, and the stock faces class action lawsuits with an August 3, 2026 deadline.
Outlook is mixed: bullish technicals and analyst consensus suggest upside to the $90 price target, but fundamental weaknesses and legal risks pose significant challenges. Investment opportunity hinges on sustained revenue growth and margin improvement, while risks include profitability pressures and litigation outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Intermediate Term Corporate Bond ETF
VCIT tracks the Bloomberg U.S. 5-10 Year Corporate Bond Index, providing exposure to investment-grade debt from industrial, utility, and financial companies. It acts as a middle-ground bond fund, offering higher yields than short-term bonds with less price volatility than long-term corporate debt.
Read more on VCIT →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
